How does the DART and juvenile toxicology assessment of a gene therapy differ from that of an oncology drug? Are you including the right studies and endpoints?
Therapeutic area can – and should – influence program design. Know for sure with answers from the experts in our new webinar series. Over the course of three presentations, you’ll learn how to design your DART program with the right approach for your therapeutic area and disease state. Discover which studies best assess the potential effects of your agent on male and female reproduction, the developing embryo/fetus, and offspring for an optimum hazard assessment.